OpSens Announces Fourth Quarter And Fiscal Year 2021 Financial Results
23 November 2021OpSens Announces Fourth Quarter And Fiscal Year 2021 Financial Results Conference call on the results today at 11 a.m. ET Quebec City, Quebec, November 23, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today reported its results for the…
OpSens Successfully Completes 20-Patient In-Human Clinical Study for TAVR Procedure
23 November 2021OpSens Successfully Completes 20-Patient In-Human Clinical Study for TAVR Procedure TAVR market outlook for procedural growth remains highly attractive globally Quebec City, Quebec, November 23, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary technology, is pleased to announce the successful treatment…
OpSens to Host Fourth Quarter Fiscal Year 2021 Financial Results Conference Call and Year-End Update on Tuesday, November 23, 2021
17 November 2021OpSens to Host Fourth Quarter Fiscal Year 2021 Financial Results Conference Call and Year-End Update on Tuesday, November 23, 2021 Conference call to be conducted at 11:00 am ET Quebec City, Quebec, November 17, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering diagnostic and treatment solutions based…
OpSens Will Participate at Stifel 2021 Virtual Healthcare Conference and Canaccord Genuity MedTech & Diagnostics Forum
10 November 2021OpSens Will Participate at Stifel 2021 Virtual Healthcare Conference and Canaccord Genuity MedTech & Diagnostics Forum Quebec City, Quebec, November 10, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company commercializing a second-generation fiber optic pressure guidewire to diagnose and treat coronary artery disease, announced today that Louis…
OpSens’ SavvyWire™ Featured at the Transcatheter Cardiovascular Therapeutics 2021 Annual Meeting in Orlando
8 November 2021OpSens’ SavvyWire™ Featured at the Transcatheter Cardiovascular Therapeutics 2021 Annual Meeting in Orlando Quebec City, Quebec, November 8, 2021 – OpSens Inc. (“OpSens” or the “Company”) (TSX:OPS) (OTCQX:OPSSF), a medical device company currently commercializing its proprietary sensing technology in the interventional cardiology market, announced that its SavvyWire, developed specifically for transcatheter aortic valve replacement (“TAVR”),…